Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | CKS1B | P61024 | 1/20 | 0.37 |
| ▸ | SKP1 | P63208 | 1/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | SRC | P12931 | 5/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18128345 | 0.78 | MTNR1A (0.42) | BCHEABCB1CKS1BSKP1SKP2 | |
| SCHEMBL16116086 | 0.78 | PTGS2 (0.40) | — | |
| SCHEMBL17119913 | 0.74 | PTGS2 (0.49) | CKS1BSKP1SKP2SCD | |
| SCHEMBL29168570 | 0.73 | BCHE (0.35) | BCHEGPR119 | |
| SCHEMBL18128350 | 0.73 | CRHBP (0.49) | — | |
| SCHEMBL5184141 | 0.73 | BCHE (0.47) | BCHEABCB1CKS1BSKP1SKP2 | |
| SCHEMBL20294404 | 0.70 | NR1H2 (0.38) | CKS1BSKP1SKP2UCHL1 | |
| SCHEMBL27653963 | 0.70 | ALDH1A1 (0.42) | — | |
| SCHEMBL27647927 | 0.70 | GPR119 (0.49) | BCHEABCB1CKS1BSKP1SKP2 | |
| SCHEMBL23727209 | 0.69 | ERN1 (0.33) | BCHEGPR119USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566025-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-01-31 | — | — | US | disclosed |
| CN-105283451-B | Novel inhibitors of viral replication | 鲁汶天主教大学 | 2021-01-26 | — | — | CN | disclosed |
| EP-2978753-B1 | NOVEL VIRAL REPLICATION INHIBITORS | UNIV LEUVEN KATH (BE) | 2020-08-12 | — | — | EP | disclosed |
| US-20200223845-A1 | NOVEL VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2020-07-16 | — | — | US | disclosed |
| US-10633378-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2020-04-28 | — | — | US | disclosed |
| US-20160297810-A1 | NOVEL VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2016-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566025-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | BCHE 3689/4885ABCB1 2581/4885CKS1B 868/4885 |
| US-20160297810-A1 | NOVEL VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, IRF3 | BCHE 3987/4885ABCB1 3425/4885CKS1B 675/4885 |
| US-10633378-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | BCHE 3689/4885ABCB1 2581/4885CKS1B 868/4885 |
| US-20200223845-A1 | NOVEL VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, IRF3 | BCHE 3987/4885ABCB1 3425/4885CKS1B 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.